“Afrigen Biologics has earned GMP certification from the South African Health Products Regulatory Authority (SAHPRA), validating Africa’s first fully integrated mRNA manufacturing facility. This milestone enhances Africa’s ability to produce investigational biological products for clinical trials, strengthens pandemic preparedness, and reduces reliance on imported vaccines.”
South Africa’s biotechnology sector has entered a defining era with Afrigen Biologics achieving Good Manufacturing Practice (GMP) certification for its Cape Town-based mRNA manufacturing facility. This achievement is not only a national triumph but also a continental breakthrough, symbolizing Africa’s growing capacity to produce advanced vaccines and biologics. GMP certification validates compliance with global safety and quality standards, enabling Afrigen to manufacture investigational biological products for Phase I and II clinical trials.
Why GMP Certification Matters
- Global Standards Compliance: GMP certification ensures adherence to internationally recognized safety and quality benchmarks.
- Clinical Trial Readiness: Afrigen can now manufacture investigational biological products for clinical trials, a critical step toward vaccine innovation.
- Health Sovereignty: By reducing reliance on imports, South Africa strengthens its ability to respond to pandemics and supply vaccines locally.
Lessons from COVID-19
The COVID-19 pandemic exposed Africa’s vulnerability in vaccine access. Wealthy nations secured doses early, while African countries faced delays and shortages. Afrigen’s facility directly addresses this inequity, ensuring that future pandemics do not leave Africa dependent on external suppliers.
Afrigen’s Journey
- 2022–2023: Conceptualization of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- 2024–2025: Infrastructure development, recruitment of scientists, and establishment of pilot production lines.
- 2026: GMP certification achieved, marking readiness for clinical trial material production.
Strategic Importance
Afrigen’s facility is more than a national achievement—it is a continental asset.
- Pandemic Preparedness: Rapid response capability for emerging infectious diseases.
- Regional Manufacturing Hub: A platform for vaccine production across Africa.
- Innovation Ecosystem: Collaboration between academia, government, and industry to advance biotechnology.
Voices of Leadership
Prof. Petro Terblanche, CEO of Afrigen, emphasized: “This certification is a tribute to the extraordinary commitment of our team. We are ready to support clinical trial production and contribute meaningfully to vaccine development.”
Economic and Social Impact
- Job Creation: Skilled employment opportunities for scientists, engineers, and technicians.
- Knowledge Transfer: Training programs to build Africa’s biotechnology workforce.
- Regional Collaboration: Partnerships with African nations to expand vaccine access.
Broader Implications for Africa
Afrigen’s GMP certification signals a shift toward biotechnology sovereignty in Africa. By localizing production, the continent reduces vulnerability to global supply chain disruptions. This achievement also positions South Africa as a leader in biotechnology innovation, capable of driving regional collaboration and industrial competitiveness.
Conclusion
Afrigen Biologics’ GMP certification is a landmark achievement for South Africa and Africa at large. It represents a decisive step toward health sovereignty, pandemic preparedness, and biotechnology innovation. As the continent continues to build capacity, Afrigen’s facility will serve as a cornerstone for vaccine development, ensuring that Africa is no longer left behind in global health crises.
